Table 2 Analysis sets and patients' characteristics at entry
Baseline Parameter* | AP (n= 16) | Placebo (n= 19) | P= |
|---|---|---|---|
Male: n (%) | 13 (81) | 14 (74) | 0.7003† |
Age: mean (SD) years | 65 (12) | 67 (15) | 0.7323‡ |
Height: mean (SD) cm | 176 (10) | 174 (8) | 0.6275‡ |
Weight: mean (SD) kg | 86 (12) | 80 (14) | 0.2207‡ |
Heart rate: mean (SD) bpm | 103 (23) | 105 (22) | 0.8510‡ |
Systolic BP: mean (SD) mmHg | 103 (26) | 110 (26) | 0.4140‡ |
Diastolic BP: mean (SD) mmHg | 52 (13) | 55 (13) | 0.4035‡ |
Temperature: mean (SD) °C | 37 (1) | 37 (1) | 0.5899‡ |
APACHE-II score: mean (SD) | 24 (7) | 23 (8) | 0.5928‡ |
SOFA score: mean (SD) | 10 (4) | 11 (5) | 0.9128‡ |
AKIN stage 1: % | 44 | 58 | 0.0657† |
AKIN stage > 1: % | 56 | 42 | |
Urine production: mean (SD) mL/kg/hour | 0.6 (0.4) | 0.6 (0.7) | 0.9245‡ |
Serum creatinine: mean (SD) μmol/L | 164 (48) | 214 (120) | 0.1108‡ |
Creatinine clearance: mean (SD) mL/minute | 50 (27) | 40 (37) | 0.3984‡ |
(Nor)epinephrine: mean (SD; n) μg/kg/min | 0.32 (0.25;13) | 0.40 (0.28;15) | 0.3418‡ |
Dopamine/dobutamine: mean (SD; n) μg/kg/min | 1.50 (2.12;2) | 0.25 (0.35;2) | 0.4975‡ |